NSCLC treatment is stage-dependent, involving surgery, chemotherapy, radiation, immunotherapy, and targeted therapy based on tumor genetics. Molecular profiling is essential for personalized treatment ...

NSCLC is the most frequent histological subtype of lung cancer, accounting for approximately 85% of patients with lung cancer. NSCLC includes a variety of different lung cancers, most notably ...

The BRAF-mutated NSCLC market is poised for growth due to an increasing incidence rate across 7MM. Currently, only one approved therapy, the Tafinlar and Mekinist combo, targets this mutation.

The Scottish Medicines Consortium has approved osimertinib for adults with unresectable stage III EGFR-mutant NSCLC whose disease has not progressed after platinum-based chemoradiation.

A new study co-led by the Institute for Systems Biology (ISB) shows that some lung cancers can change identity as they evolve ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...

Researchers have built an AI-powered pathology tool designed to predict whether small cell lung cancer patients will respond ...

You and your family are our top priority. At Fred Hutch Cancer Center, we offer comprehensive and compassionate care — personalized to you. You'll have access to the latest treatment options, clinical ...

The National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) guidelines differ regarding recommended treatments for ...

Results of a new study conclude that a pathology tool powered by artificial intelligence can predict whether a patient with ...

A patient walks into a thoracic surgery consultation with a small lung tumor, stage I on every scan, and every conventional ...